Sotorasib vs Adagrasib: Two KRAS G12C Inhibitors Compared
Sotorasib and adagrasib are both oral covalent inhibitors of KRAS G12C, and both lock the mutant protein in its inactive state. They are not interchangeable in every respect: pharmacology, brain penetration and side-effect patterns differ, and head-to-head data are limited.
Quick Answer
Sotorasib and adagrasib are both oral covalent inhibitors of KRAS G12C, and both lock the mutant protein in its inactive state. They are not interchangeable in every respect: pharmacology, brain penetration and side-effect patterns differ, and head-to-head data are limited.
Side-by-side comparison
Sotorasib and adagrasib inhibit KRAS G12C by the same covalent mechanism but differ in pharmacology, central-nervous-system data and monitoring. There is no adequately powered head-to-head trial.
| Feature | Sotorasib | Adagrasib |
|---|---|---|
| Dosing | Once daily | Twice daily |
| Half-life | Shorter | Longer; designed for sustained target coverage |
| CNS penetration | Limited data | Documented intracranial activity |
| Drug interactions | Fewer; absorption reduced by acid-lowering drugs | CYP3A substrate and inhibitor; more interactions |
| Cardiac effect | No notable QT signal | Can prolong the QT interval |
| Prominent toxicity | Hepatotoxicity, especially soon after immunotherapy | Nausea, diarrhoea and vomiting; QT prolongation |
Same Target, Same Mechanism
Both drugs bind the switch-II pocket of GDP-bound KRAS G12C and form a covalent bond with cysteine 12, preventing nucleotide exchange and shutting down RAF-MEK-ERK output. Both require the exact G12C alteration and are inactive against other KRAS mutations.
Cross-resistance is expected for shared on-target mechanisms, such as a secondary mutation in the drug-binding pocket, though the specific mutations selected can differ.
Pharmacology Differences
Adagrasib has a longer half-life and was designed for sustained target coverage; it is dosed twice daily. Sotorasib is dosed once daily. Adagrasib is a CYP3A substrate and inhibitor with more drug-interaction considerations, and it can prolong the QT interval.
Adagrasib has measurable central nervous system penetration and has shown intracranial activity, which is relevant because KRAS G12C lung cancer can involve the brain.
Toxicity Patterns
Both cause gastrointestinal effects and liver enzyme elevations. Adagrasib's gastrointestinal burden (nausea, diarrhoea, vomiting) and QT effects are notable; sotorasib's hepatotoxicity, sometimes overlapping with prior or subsequent immunotherapy, has been a particular focus.
The clinically meaningful differences are in monitoring and management rather than in whether the drug works.
How to Read the Comparison
Reported response rates in previously treated KRAS G12C lung cancer are broadly similar (around a third), with overlapping confidence intervals and no adequately powered head-to-head trial. Choice in practice is influenced by CNS disease, interacting medications, cardiac history and local availability.
Both are being tested in earlier lines and in combinations, so the comparison will keep evolving.
Monitoring Differences
Both drugs require liver-enzyme monitoring and active management of gastrointestinal effects, but the emphasis differs. With sotorasib the main watch-point is hepatocellular injury, particularly when an immune-checkpoint inhibitor was used shortly beforehand. With adagrasib, baseline and on-treatment ECGs, correction of electrolytes, and a careful review of concomitant QT-prolonging or CYP3A-interacting medicines are added.
Neither profile makes one drug categorically safer; they shift which parameters are followed and which co-medications need adjusting. Where clinical factors are balanced, local availability and prescriber familiarity often settle the choice.
Key Takeaways
- ·Sotorasib and adagrasib share the same covalent KRAS G12C mechanism and mutation requirement.
- ·Adagrasib has a longer half-life, more drug interactions and QT effects, and better documented CNS activity.
- ·There is no powered head-to-head trial; selection is driven by CNS disease, comorbidity and interactions.
Put these genes in pathway context
Frequently asked questions
Is one KRAS G12C inhibitor clearly more effective?
No adequately powered head-to-head trial exists. Reported response rates in previously treated lung cancer are broadly similar, with overlapping confidence intervals.
Which one is preferred for brain metastases?
Adagrasib has better-documented central-nervous-system penetration and intracranial activity, which can influence the choice when brain disease is present.
Do the drugs differ in drug interactions?
Yes. Adagrasib is a CYP3A substrate and inhibitor and can prolong the QT interval, so it carries more interaction and cardiac-monitoring considerations than sotorasib.
References
Continue Reading
How Sotorasib Works: Locking KRAS G12C in Its Off State
4 min read
KRAS G12C in Colorectal Cancer: Biomarker Context
4 min read
KRAS G12C vs G12D: Similar Gene, Different Alterations
2 min read
MAPK Pathway Resistance: A Framework for Reading Resistance Reports
2 min read
Gene Mutations That Cause Disease
5 min read
Liquid Biopsy vs Tissue Testing: What Each Sample Can Tell You
2 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
KRAS has 500+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.